Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 12/20 | 0.58 |
| ▸ | CTSB | P07858 | 3/20 | 0.58 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741406 | 1.00 | CAPN1 (0.58) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL7206790 | 0.82 | CTSK (0.76) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL913603 | 0.82 | CTSK (0.76) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL6735420 | 0.82 | CTSK (0.76) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL7615476 | 0.81 | CAPN1 (0.58) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL2730672 | 0.81 | CTSK (0.74) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL913547 | 0.81 | CTSK (0.74) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL11063045 | 0.79 | CAPN1 (0.68) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL6735494 | 0.79 | CTSK (0.53) | CAPN1CTSBCAPN9MAPK1CTSK | |
| SCHEMBL6742229 | 0.79 | CTSK (0.60) | CAPN1CTSBCAPN9MAPK1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689785-B2 | USEFUL PARTICULARLY AS REMEDIES FOR BONE DISEASES AND ARTHRITIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-02-10 | — | — | US | disclosed |
| EP-1342720-A2 | Epoxysuccinamide derivatives | NIPPON CHEMIPHAR CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1022276-B1 | EPOXYSUCCINAMIDE DERIVATIVES | NIPPON CHEMIPHAR CO (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-20020091131-A1 | Epoxysuccinamide derivatives | VELCURA THERAPEUTICS, INC. | 2002-07-11 | — | — | US | disclosed |
| US-6387908-B1 | BONE DISORDERS; ANTIARTHRITIC AGENTS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| EP-1022276-A1 | EPOXYSUCCINAMIDE DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091131-A1 | Epoxysuccinamide derivatives | NR0B1, NR2E1, NR4A1 | CAPN1 3204/4885CTSB 3812/4885CAPN9 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.